Board of Directors

Lawson Macartney, DVM, Ph.D.; Chairman

Dr. Macartney has served as the Chairperson of our Board since May 2015 and as a member of our Board since May 2014. From January 2017 to June 2017, Dr. Macartney served as CEO of Scout Bio Inc., a gene therapy company developing therapies for companion animals. Dr. Macartney serves on the Board of Dechra PLC, an international animal health pharmaceutical company based in the United Kingdom, and on the Supervisory Board of the Netherlands Translational Research Centre, a preclinical biopharmaceutical company based in The Netherlands. He served as President, Chief Executive Officer and a member of the board of directors of Ambrx Inc., a biopharmaceutical company, from February 2013 to June 2015. Prior to Ambrx, Dr. Macartney served at Shire AG, a specialty biopharmaceutical company, as Senior Vice President of the Emerging Business Unit, where he was responsible for discovery initiatives through Phase 3 development of Shire’s Specialty Pharmaceutical portfolio. Prior to joining Shire AG, he served at GSK, a pharmaceutical company, from 1999 to 2011, serving as Senior Vice President of Global Product Strategy and Project/Portfolio Management from 2007 to 2011, as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007, and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004. Prior to joining GSK, Dr. Macartney was employed at Astra Pharmaceuticals in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc., a pharmaceutical company. Dr. Macartney received his Ph.D. from Glasgow University in Scotland, where he was a Royal Society Research Fellow, and his B.V.M.S. (equivalent to a D.V.M.) from Glasgow University Veterinary School. He is also trained in diagnostic pathology and is a Fellow of the Royal College of Pathologists.

Matthew W. Foehr

Mr. Foehr has served as Chief Executive Officer of OmniAb, Inc. (Nasdaq: OABI) since November of 2022 and has over 25 years of experience in the pharmaceutical industry, having managed global operations, technology innovation and research and development programs in a variety of therapy areas. Prior to OmniAb, he was Chief Operating Officer at Ligand Pharmaceuticals Incorporated from 2011 to 2022. Prior to Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GSK. Following GSK’s $3.6 billion acquisition of Stiefel Laboratories, Inc., a pharmaceutical company, in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation, a pharmaceutical company, including Senior Vice President of Technical Operations and Vice President of Manufacturing. Early in his career, Mr. Foehr managed manufacturing activities and worked in process sciences at both LXR Biotechnology Inc. and Berlex Biosciences. Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his Bachelor of Science degree in Biology from Santa Clara University.

Kathy Rouan, Ph.D.

Dr. Rouan has nearly 30 years of pharmaceutical industry experience and most recently served as senior vice president and head of Projects, Clinical Platforms and Sciences (PCPS) at GlaxoSmithKline (GSK). GSK’s PCPS encompasses the company’s global clinical operations, statistics and programming, clinical pharmacology, GCP quality, third party resourcing and project management functions and includes approximately 1,800 individuals in 20 countries. Dr. Rouan first joined GSK in 1989 with a background in pharmaceutical sciences, focusing on formulation development of protein pharmaceuticals. In 1993, she transitioned into project leadership and management becoming vice president and head of metabolism and pulmonary project management in 1999. In 2007, Dr. Rouan led the development, submission and approval of Arzerra® (ofatumumab) for refractory chronic lymphocytic leukemia. In 2012, she became head of biopharmaceutical development, assuming responsibility for delivery of GSK’s portfolio of biopharmaceutical medicines. In December 2013, Dr. Rouan was appointed senior vice president and head of research and development for Stiefel, GSK’s dermatology therapy area unit. Dr. Rouan earned a Ph.D. in pharmaceutical sciences from the University of Rhode Island and a B.Pharm. from the University of London.

Charles A. Rowland Jr.

Mr. Rowland has more than 30 years of biopharmaceutical industry experience and is currently a board member and strategic advisor for multiple biotechnology companies. He most recently served as the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to his tenure with Aurinia Pharmaceuticals, he was the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was Executive Vice President and CFO, as well as interim co-CEO, for Endo Pharmaceuticals, a specialty pharmaceutical company with $1.3 billion in revenues. He previously held finance and operational positions of increasing responsibility at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb. Mr. Rowland currently serves as a member of the board of directors for Blueprint Medicines and Nabriva Therapeutics, with previous board appointments including Vitae Pharmaceuticals, BIND Therapeutics, Aurinia Pharmaceuticals and Idenix Pharmaceuticals, among others. Mr. Rowland holds an MBA from Rutgers University and a Bachelor of Science degree from Saint Joseph’s University.

Matthew Singleton

In October 2011, Mr. Singleton retired from his position as Executive Vice President and Chief Financial Officer of CitationAir (formerly CitationShares LLC), a privately-held jet services company wholly-owned by Textron Inc., a public industrial conglomerate. He had served in this position since 2000. Mr. Singleton has extensive financial, accounting and transactional experience, including through his role as Managing Director, Executive Vice President and Chief Administrative Officer of CIBC World Markets, an investment banking company, for 20 years, at Arthur Andersen & Co., a public accounting firm, including as Partner-in-Charge of the Metro New York Audit and Business Advisory Practice, and as a Practice Fellow at the Financial Accounting Standards Board, a private organization responsible for establishing financial accounting reporting standards. From 2003 until 2014, Mr. Singleton served as a director of Cubist Pharmaceuticals Inc., and as Audit Committee Chair beginning in 2004. Mr. Singleton previously served as an independent director of Salomon Reinvestment Company Inc., a privately-held investment services company. Mr. Singleton received an AB in Economics from Princeton University and his MBA from New York University with a focus in Accounting.

Brian Lian, Ph.D.

Dr. Lian’s bio is provided under Management.